Shots:

• The companies collaborated to evaluate the safety, PK, PD & preliminary efficacy of the combination therapy of Innovent’s sintilimab + NeoCura’s NEO_PLIN2101 in patients with cancer
• The collaboration will bolster the clinical development of combination immunotherapy for multiple solid tumors & the companies plan to submit an IND application to the NMPA imminently
• Innovent is currently conducting 20+ clinical studies of sintilimab to assess safety and efficacy for multiple cancer indications including 10+ registrational or pivotal clinical trials. Additionally, sintilimab is currently under review in China & has one regulatory submission for the 1L treatment of ESCC

 ­ | Ref: PR Newswire | Image: Innovent